New advances in targeted therapies for squamous cell carcinoma of the head and neck

Anti-Cancer Drugs

Volumn 22, Issue 7, 2011, Pages 626-633

  MacHiels, Jean Pascal ^a   Schmitz, Sandra ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

epidermal growth factor receptor; squamous cell carcinoma; targeted agents; tyrosine kinase receptors

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; ZALUTUMUMAB;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BACTEREMIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RECEPTOR BINDING; DRUG RESPONSE; FEBRILE NEUTROPENIA; HEAD AND NECK CARCINOMA; HUMAN; HYPERGLYCEMIA; LIVER FAILURE; LOADING DRUG DOSE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION RESPONSE; RECOMMENDED DRUG DOSE; REVIEW; SQUAMOUS CELL CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION;

EID: 79960446890     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328341071e     Document Type: Review

References (71)

1. Forastiere AA, Trotti A, Pfister DG, Grandis JR. Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006; 10:2603-2605. (Pubitemid 46622079)
2. Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med 2008; 11:1116-1127.
3. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366:2-16. (Pubitemid 43199589)
4. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24:2666-2672. (Pubitemid 46622088)
5. Rubin Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA,Wagener MM, et al. Levels of TGFA and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824-832. (Pubitemid 28280548)
6. Psyrri A, Yu Z, Weinberger PM, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11:5856-5862. (Pubitemid 41170313)
7. Mrhalova M, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor: its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinoma. Neoplasm 2005; 52:338-343. (Pubitemid 41076203)
8. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-4176. (Pubitemid 46622295)
9. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome. J Clin Oncol 2007; 25:2164-2170.
10. Chiang WF, Liu SY, Yen CY, Lin CN, Chen YC, Lin SC, Chang KW. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinoma. Oral Oncol 2008; 44:270-276.
11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
12. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-28.
13. Stewart JS, Cohen EE, Licitra L, Van Herpen C, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864-1871.
14. Machiels JP, Subramian S, Ruzsa A, Repassy G, Lifrenko I, Flygare A, et al. An open-label, randomized phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFR) antibody, versus best supportive care in patients with non-curable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based therapy. J Clin Oncol 2010; 28 (Suppl):LBA5506. (abstr.)
15. Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol 2009; 27 (Suppl):6011. (abstr.)
16. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO foundation study. Clin Cancer Res 2010; 16:2474-2482.
17. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005; 280:31182-31189. (Pubitemid 41291855)
18. Dittmann K, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP. Celecoxib-induced tumor cell radio sensitization by inhibiting radiation induced nuclear EGFR transport and DNA repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys 2008; 70:203-212. (Pubitemid 350251053)
19. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005; 76:157-161. (Pubitemid 41725442)
20. Walker F, Zhang HH, Burgess AW. Identification of a novel EGF-sensitive cell cycle checkpoint. Exp Cell Res 2007; 313:511-526. (Pubitemid 46186303)
21. Milas L, Mason K, Hunter N. In-vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6:701-708. (Pubitemid 30111496)
22. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-3243. (Pubitemid 32591441)
23. Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009; 90:166-171.
24. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced squamous cell head and neck cancer: a pilot phase II study for a new combined-modality paradigm. J Clin Oncol 2006; 24:1072-1078. (Pubitemid 46638804)
25. Langer CJ, Lee JW, Patel UA, Shin DM, Argiris AE, Quon H, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2008; 26 (Suppl):6006. (abstr.)
26. Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2010 [Epub ahead of print]. doi: 10.1093/annonc/mdq216.
27. Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010; 21:342-347.
28. Chen C, Kane M, Song J, Campana J, Raben A, Hu K, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007; 25:4880-4886. (Pubitemid 350220417)
29. Van Waes C, Allen CT, Citrin D, Gius D, Colevas AD, Harold NA, et al. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2010; 77:447-454.
30. Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:4448-4453.
31. Mesia R, Vázquez S, Grau JJ, Garćia-Sáenz JA, Bayona C, Galceran JC, et al. A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. J Clin Oncol 2009; 27 (Suppl):6015. (abstr.)
32. Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28:8-14.
33. Wanebo H, Ghebremichael MS, Burtness B, Ridge JA, Spencer S, Rosen FR, et al. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: primary site organ preservation and disease control at 2 years (ECOG, E2303). J Clin Oncol 2010; 28 (Suppl):5513. (abstr.)
34. Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M, Ang KK. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 2007; 67:568-572. (Pubitemid 46108328)
35. Cohen E, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2010; 28:3336-3343.
36. Ferris RL, Heron DE, Kim S, Gibson MK, Posluszny D, Seethala RR, et al. Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): mature results with HPV analysis. J Clin Oncol 2010; 28 (Suppl):5515. (abstr.)
37. Mesia R, Rueda A, Vera R, Lozano A, Medina JA, Aguiar Bujanda D, et al. Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial. J Clin Oncol 2010; 28 (Suppl):5534. (abstr.)
38. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-5587.
39. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, et al. Phase II multicenter study of the epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of head and neck. J Clin Oncol 2005; 23:5568-5577.
40. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008; 112:2710-2719. (Pubitemid 351969215)
41. Cohen E. Role of epidermal growth factor receptor pathway targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24:2659-2665. (Pubitemid 46622087)
42. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19:2013-2023. (Pubitemid 47353811)
43. Abidoye OO, Cohen EE, Wong SJ, Wong SJ, Kozloff MF, Nattam SR, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006; 24 (Suppl):5568. (abstr.)
44. Harrington KJ, Berrier A, Robinson M, Remenar E, Housset M, Hurtado de Mendoza F, et al. Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2010; 28 (Suppl):5505. (abstr.)
45. Specenier PM, Lalami Y, Vermorken J, Lacombe D, El-Hariry I, Bogaerts J, Awada A. EORTC 24051: unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC). J Clin Oncol 2009; 27 (Suppl):6017. (abstr.)
46. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, et al. Phase I Trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010; 28:3965-3972.
47. Seiwert TY, Clement PM, Cupissol D, Del Campo J, De Mont-Serrat H, Thurm HC, et al. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: preliminary results of a randomized, open-label phase II study. J Clin Oncol 2010; 28 (Suppl):5501. (abstr.)
48. Torres MA, Raju U, Molkentine D, Riesterer O, Milas L, Ang KK. AC 480, formerly BMS-599626, a pan HER inhibitor, enhances radio sensitivity and radio response of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs 2010 [Epub ahead of print]. doi:10.1007/s10637-010-9389-3
49. Le Tourneau C, Winquist E, Hotte SJ, Laurie SA, Soulieres D, Chia SK, et al. Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2010; 28 (Suppl):5531. (abstr.)
50. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009; 15:3740-3750.
51. Seiwert T, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinalli M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69:3021-3031.
52. Egloff AM, Grandis J.R. Targeting epidermal growth factor receptor and Src pathways in head and neck cancer. Semin Oncol 2008; 35:286-297. (Pubitemid 351787698)
53. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55:2463-2469.
54. Jun H, Chang M, Ko Y, Jeong H, Son Y, Baek J, et al. Clinical significance of type 1 insulin-like growth factor receptor and insulin-like growth factor binding protein-3 expression in squamous cell carcinoma of head and neck. J Clin Oncol 2009; 27 (Suppl):6036. (abstr.)
55. Schmitz S, Kaminsky-Forrett M, Henry S, Zanetta S, Geoffrois L, Bompas E, et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02. J Clin Oncol 2010; 28 (Suppl):5500. (abstr.)
56. Courtney KD, Corcoran RB, Engelman JA. The PI3 K Pathway as drug target in human cancer. J Clin Oncol 2010; 28:1075-1083.
57. Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T, Stahl U. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 2002; 198:335-342. (Pubitemid 35277384)
58. Qiu W, Schönleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12:1441-1446.
59. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, Gonzalez MV. Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005; 114:242-248. (Pubitemid 40194293)
60. Garrido-Laguna I, Janku F, Tsimberidou A,Wheler J, Falchook GS, Fu S, et al. Phosphatase and tensin homologue (PTEN) loss and response to phase I trials targeting PI3K/AKT/mTOR pathway in patients with advanced cancer. J Clin Oncol 2010; 28 (Suppl):e13018. (abstr.)
61. Janku F, Tsimberidou AM, Garrido-Laguna I, Hong DS, Naing A, Falchook GS, et al. PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. J Clin Oncol 2010; 28 (Suppl):2583. (abstr.)
62. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, et al. Mammalian target of rapamycin: a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005; 65:9953-9961. (Pubitemid 41541476)
63. Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C, et al. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 2001; 111:1834-1841. (Pubitemid 32946463)
64. Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, et al. Vascular endothelial growth factor receptor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003; 25:464-474. (Pubitemid 36577031)
65. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005; 11:1434-1440. (Pubitemid 40315223)
66. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25:3766-3773. (Pubitemid 47372619)
67. Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0420. J Clin Oncol 2010; 28:3330-3335.
68. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28:21-28.
69. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10:247-257.
70. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-1417.
71. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 2010; 16:2489-2495.